Fenestrated AAA Endovascular Graft Post-Approval Study
- Conditions
- Abdominal Aortic Aneurysm (AAA)Juxtarenal AneurysmAorto-iliac Aneurysm
- Interventions
- Device: Zenith® Fenestrated AAA Endovascular Graft
- Registration Number
- NCT01990950
- Lead Sponsor
- Cook Research Incorporated
- Brief Summary
This post-market study is approved by the US FDA to evaluate the long-term safety and performance of the Zenith® Fenestrated AAA Endovascular Graft.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
- abdominal aortic and aortoiliac aneursyms with a diameter greater than or equal to 5 cm
- aortic or aortoiliac aneurysm with a history of growth greater than or equal to 0.5 cm per year, or clinical indication for AAA repair
- proximal neck less than 4mm or greater than or equal to 15 mm in length unless otherwise compromised to preclude seal
- renal artery stenosis greater than 50 percent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Zenith® Fenestrated AAA Endovascular Graft Zenith® Fenestrated AAA Endovascular Graft -
- Primary Outcome Measures
Name Time Method Treatment Success : AAA Related Mortality 5 years patients treated with the Zenith® Fenestrated AAA Endovascular Graft will have a rate of aneurysm-related mortality at 5 years that meets a performance goal of 18% ,
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Borgess Research Institute
🇺🇸Kalamazoo, Michigan, United States
Newark Beth Israel Medical Center
🇺🇸Newark, New Jersey, United States
University of California-Davis
🇺🇸Sacramento, California, United States
University of Colorado
🇺🇸Aurora, Colorado, United States
Wake Forest University Health
🇺🇸Winston-Salem, North Carolina, United States
University of Wisconsin Hospital and Clinics
🇺🇸Madison, Wisconsin, United States